BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback